Consumer biomarker-testing kits (like 23andme, and the equivalents for whole-genome sequencing, proteomics, microbiome, etc) don't make a ton of practical sense to me as a path towards new medical treatments.
Usable in the sense of "objectively a good predictor" is a hell of a long way from usable in the sense of "doctors and insurers will trust it." Which means that your market has to be scientifically literate, which is a small # of people.
-
-
Didn't know that about medical geneticists pushing PRS's; good to hear!
- 3 more replies
New conversation -
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.